Mirabegron — Beta-3 adrenergic agonist. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Mirabegron
Class
Beta-3 adrenergic agonist
Mechanism
Activates beta-3 receptors, relaxing the detrusor during bladder filling and increasing bladder capacity.
Used for
Overactive bladder in adults with urgency, urinary frequency or urge incontinence; Neurogenic detrusor overactivity in children aged 3 or older who weigh at least 35 kg, for the cited extended-release tablets
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260903 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Relaxes bladder smooth muscle by a direct antispasmodic effect and by inhibiting the muscarinic action of acetylcholine.
On both cards: Common side effects — Headache · Warnings — Angioedema
Only on the Oxybutynin card: Used for — Overactive bladder with urge urinary incontinence, urgency and frequency; Symptoms of detrusor overactivity associated with a neurological condition in children aged 6 or older · Common side effects — Dry mouth; Constipation; Diarrhea; Somnolence · Warnings — Urinary retention, gastric retention or severe decreased gastrointestinal motility; uncontrolled narrow-angle glaucoma are contraindications; Anticholinergic CNS effects · Interactions — Other anticholinergic drugs; Prokinetic agents (metoclopramide)
On both cards: Common side effects — Urinary tract infection · Warnings — Urinary retention (outlet obstruction)
Only on the Solifenacin card: Used for — Overactive bladder with urgency, urinary frequency or urge urinary incontinence in adults · Common side effects — Dry mouth; Constipation; Blurred vision · Warnings — Angioedema and anaphylaxis; QT prolongation in high-risk patients · Interactions — Strong CYP3A4 inhibitors (e.g., ketoconazole)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera